| Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ... Nature communications 12 (1), 729, 2021 | 239 | 2021 |
| The association between tumor mutational burden and prognosis is dependent on treatment context C Valero, M Lee, D Hoen, J Wang, Z Nadeem, N Patel, MA Postow, ... Nature genetics 53 (1), 11-15, 2021 | 158 | 2021 |
| Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma AS Ho, A Ochoa, G Jayakumaran, A Zehir, CV Mayor, J Tepe, V Makarov, ... The Journal of clinical investigation 129 (10), 4276-4289, 2019 | 150 | 2019 |
| Response rates to anti–PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase C Valero, M Lee, D Hoen, A Zehir, MF Berger, VE Seshan, TA Chan, ... JAMA oncology 7 (5), 739-743, 2021 | 145 | 2021 |
| Improved prediction of immune checkpoint blockade efficacy across multiple cancer types D Chowell, SK Yoo, C Valero, A Pastore, C Krishna, M Lee, D Hoen, ... Nature biotechnology 40 (4), 499-506, 2022 | 144 | 2022 |
| Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer C Valero, L Pardo, M López, J García, M Camacho, M Quer, X León Head & neck 39 (2), 219-226, 2017 | 89 | 2017 |
| Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy M Lee, RM Samstein, C Valero, TA Chan, LGT Morris Human vaccines & immunotherapeutics 16 (1), 112-115, 2020 | 65 | 2020 |
| Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma C Valero, L Pardo, A Sansa, J Garcia Lorenzo, M Lopez, M Quer, X León Head & Neck 42 (2), 336-343, 2020 | 53 | 2020 |
| The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: a comparative study B Xu, AM Salama, C Valero, A Yuan, A Khimraj, M Saliba, DK Zanoni, ... Virchows Archiv, 1-10, 2021 | 52 | 2021 |
| Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer C Valero, DK Zanoni, MR McGill, I Ganly, LGT Morris, M Quer, JP Shah, ... Cancer 126 (5), 994-1003, 2020 | 47 | 2020 |
| Head and neck paragangliomas: 30‐year experience C Valero, I Ganly, JP Shah Head & neck 42 (9), 2486-2495, 2020 | 37 | 2020 |
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity X Ma, N Riaz, RM Samstein, M Lee, V Makarov, C Valero, D Chowell, ... Nature genetics 54 (7), 996-1012, 2022 | 36 | 2022 |
| Host factors independently associated with prognosis in patients with oral cavity cancer C Valero, DK Zanoni, A Pillai, I Ganly, LGT Morris, JP Shah, RJ Wong, ... JAMA Otolaryngology–Head & Neck Surgery 146 (8), 699-707, 2020 | 31 | 2020 |
| Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade SK Yoo, D Chowell, C Valero, LGT Morris, TA Chan JAMA Network Open 5 (2), e220448-e220448, 2022 | 30 | 2022 |
| Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients K Majercakova, C Valero, M López, J García, N Farré, M Quer, X León Oral Oncology 77, 37-42, 2018 | 23 | 2018 |
| Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types N Sinha, S Sinha, C Valero, AA Schäffer, K Aldape, K Litchfield, TA Chan, ... Cancer research 82 (11), 2076-2083, 2022 | 22 | 2022 |
| A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer P Demetrio de Souza Franca, S Kossatz, C Brand, D Karassawa Zanoni, ... European journal of nuclear medicine and molecular imaging 48 (11), 3618-3630, 2021 | 22 | 2021 |
| Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade SK Yoo, D Chowell, C Valero, LGT Morris, TA Chan Npj Precision Oncology 6 (1), 23, 2022 | 20 | 2022 |
| High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab CH Lee, RG DiNatale, D Chowell, C Krishna, V Makarov, C Valero, ... Molecular Cancer Research 19 (9), 1510-1521, 2021 | 20 | 2021 |
| The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma L Pardo, C Valero, M López, J García, M Camacho, M Quer, X León Auris Nasus Larynx 44 (3), 313-318, 2017 | 18 | 2017 |
